Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProTrials Research, a clinical research organization, has announced that Medivation has selected the company to conduct separate international Phase III clinical trials for two novel treatments. ProTrials will test "MDV3100" for treating prostate cancer and the investigational drug "Dimebon" as a treatment for Huntington’s disease. The clinical trials will involve hundreds of patients and 125 test sites.
Subscribe to our email newsletter
ProTrials will direct the Huntington’s trial across the US, Canada and Europe. Moreover, the company will also manage prostate cancer trial in the US and Canada.
Jodi Andrews, CEO, ProTrials, said: “Medivation’s repeated selection of ProTrials as a clinical trials partner is a nod to our track record of efficiency, cost effectiveness and most importantly, our GCP compliance in conducting clinical trials.”
“with prostate cancer being one of the most prevalent types of cancer in men, and Huntington’s disease having no treatments currently approved by the US Food and Drug Administration, these Phase III clinical trials are crucial for moving potentially life-saving treatments to market, he added.